Biomarkers Predict Metastatic Melanoma Responses to Anti-PD-1 Immunotherapy.

This retrospective study looked at the clinical, histologic, and molecular predictors of response to checkpoint inhibitor therapy for patients with metastatic melanoma. Better objective response rates were associated with metachronous metastases, PD-L1 status, CD163+ histiocytes at advancing edges, and NRAS mutations. Metachronous metastases were associated with longer progression-free survival and overall survival. These biomarkers should be used for therapeutic decision-making relating to PD-1 immunotherapy.

https://www.nature.com/articles/s41416-018-0168-9